Advertisement

Annals of Surgical Oncology

, Volume 19, Issue 1, pp 184–191 | Cite as

Incorporation of Adjuvant Therapy into the Multimodality Management of Gastrointestinal Stromal Tumors of the Stomach in the United States

  • Karl Y. Bilimoria
  • Jeffrey D. Wayne
  • Ryan P. Merkow
  • Daniel E. Abbott
  • Janice N. Cormier
  • Barry W. Feig
  • Kelly K. Hunt
  • Peter W. T. Pisters
  • Raphael Pollock
  • David J. Bentrem
Bone and Soft Tissue Sarcomas

Abstract

Background

Gastrointestinal stromal tumors (GIST) treatment changed considerably with introduction of imatinib in 2001 and reports of early successes. However, little is known about imatinib incorporation into practice. Our objective was to examine the integration of adjuvant systemic therapy into GIST management.

Methods

Patients with gastric GIST were identified (n = 4508) from the National Cancer Data Base (2001–2007). Separate regression models were developed to examine factors associated with adjuvant and neoadjuvant therapy use.

Results

A total of 3050 patients underwent surgical resection. From 2001–2003 to 2006–2007, use of adjuvant therapy increased from 29 to 47% (P < 0.001). Patients were less likely to receive adjuvant therapy if tumors were <3 cm, low grade, had negative margins, were treated at low-volume centers, or were diagnosed during 2001–2003 (P < 0.01). Adjuvant systemic therapy for lesions <3 cm also increased (17 to 25%, P = 0.001). For high-risk GISTs, adjuvant therapy use increased from 41 to 58% overall, with increases of 46 to 70% at high-volume centers and 40 to 48% at low-volume centers (P < 0.001). Neoadjuvant therapy increased from 0 to 8%; patients were more likely to receive neoadjuvant treatment if their tumor was >6 cm, treated at high-volume centers, or were diagnosed during 2006–2007 (P < 0.001).

Conclusions

Adjuvant systemic therapy use for GISTs was increasing and widespread prior to FDA approval of adjuvant imatinib, suggesting that contemporaneous advances in management of advanced GIST were being simultaneously and rapidly translated into the adjuvant setting. As relatively costly therapies are integrated into practice, more robust tracking systems are needed to monitor the incorporation of new treatments.

Keywords

Imatinib National Comprehensive Cancer Network Adjuvant Systemic Therapy National Cancer Data Base Gastric Gist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Lemonick M, Park A, Cray D, Gorman C. New hope for cancer. Time. 2001;157:62–9.PubMedGoogle Scholar
  4. 4.
    Blanke CD, von Mehren M, Joensuu H, Roberts PJ, et al. Evaluation of the safety and efficacy of an oral molecularly-targeted, STI571, in patients with unresectable or metastatic gastrointestinal stromal tumors expressing C-KIT (CD117). Proc Am Soc Clin Oncol. 2001 (abstr 1).Google Scholar
  5. 5.
    Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344:1052–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–80.PubMedCrossRefGoogle Scholar
  7. 7.
    Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26:620–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008;26:626–32.PubMedCrossRefGoogle Scholar
  9. 9.
    Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127–34.PubMedCrossRefGoogle Scholar
  10. 10.
    DeMatteo RP, Owzar K, Antonescu CR, Maki R, Demetri D, McCarter M, et al. Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: the U.S. Intergroup phase II trial ACOSOG Z9000. Proc Am Soc Clin Oncol. 2008 (abstr 8).Google Scholar
  11. 11.
    Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:1097–104.PubMedCrossRefGoogle Scholar
  12. 12.
    DeMatteo RP, Owzar K, Maki R, Pisters P, Blackstein M, Antonescu C, et al. Adjuvant imatinib mesylate increases recurrence free survival in patients with completely resected localized primary gastrointestinal stromal tumor: North American Intergroup Phase III trial ACOSOG Z9001. Proc Am Soc Clin Oncol. 2007 (abstract 10079).Google Scholar
  13. 13.
    Eisenberg BL, Harris J, Blanke CD, Demetri GD, Heinrich MC, Watson JC, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol. 2009;99:42–7.PubMedCrossRefGoogle Scholar
  14. 14.
    McAuliffe JC, Hunt KK, Lazar AJ, Choi H, Qiao W, Thall P, et al. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol. 2009;16:910–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Cancer Netw. 2010; 8 Suppl 2:S1–41; quiz S42–4.Google Scholar
  16. 16.
    Balas E, Boren S. Managing clinical knowledge for health care improvement. In: Bemmel J, Mc Cray AT, editors. Yearbook of medical informatics 2000: patient-centered systems. Stuttgart: Schattauer; 2000. p. 65–70.Google Scholar
  17. 17.
    Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15:683–90.PubMedCrossRefGoogle Scholar
  18. 18.
    Winchester DP, Stewart AK, Bura C, Jones RS. The National Cancer Data Base: a clinical surveillance and quality improvement tool. J Surg Oncol. 2004;85:1–3.PubMedCrossRefGoogle Scholar
  19. 19.
    Bilimoria KY, Bentrem DJ, Stewart AK, Winchester DP, Ko CY. Comparison of commission on cancer-approved and -nonapproved hospitals in the United States: implications for studies that use the National Cancer Data Base. J Clin Oncol. 2009;27:4177–81.PubMedCrossRefGoogle Scholar
  20. 20.
    International Classification of Disease for Oncology. 3rd ed. Geneva: World Health Organization, 2000.Google Scholar
  21. 21.
    Facility Oncology Registry Data Standards. Chicago: Commission on Cancer, 2004.Google Scholar
  22. 22.
    Department of Health and Human Services. The International Classification of Diseases. 9th revised. clinical modification: ICD-9-CM. Washington, DC: Government Printing Office, 1998.Google Scholar
  23. 23.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.PubMedCrossRefGoogle Scholar
  24. 24.
    Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Commission on Cancer: Approvals Categories. Available at http://www.facs.org/cancer/coc/categories.html. Accessed December 17, 2006.
  26. 26.
    Panageas KS, Schrag D, Riedel E, Bach PB, Begg CB. The effect of clustering of outcomes on the association of procedure volume and surgical outcomes. Ann Intern Med. 2003;139:658–65.PubMedGoogle Scholar
  27. 27.
    Hosmer J, Lemeshow S. Applied logistic regression. New York: Wiley, 1999.Google Scholar
  28. 28.
    Eckhauser F, Yahanda A, Greenson J. Gastric smooth muscle tumors. In: Cameron J, editor. Current surgical therapy, 3rd ed. St. Louis: Mosby; 1998. p. 114–7.Google Scholar
  29. 29.
    Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33:459–65.PubMedCrossRefGoogle Scholar
  30. 30.
    Miettinen M, El-Rifai W, Sobin LH, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol. 2002;33:478–83.Google Scholar
  31. 31.
    Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006;130:1466–78.PubMedGoogle Scholar
  32. 32.
    Huse DM, von Mehren M, Lenhart G, Joensuu H, Blanke C, Feng W, et al. Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours. Clin Drug Investig. 2007;27:85–93.PubMedCrossRefGoogle Scholar
  33. 33.
    Joensuu H, Trent JC, Reichardt P. Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treat Rev. 2011;37:75–88.PubMedCrossRefGoogle Scholar
  34. 34.
    Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008;26:5352–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Van Glabbeke M, Verweij J, Casali PG, Le Cesne A, Hohenberger P, Ray-Coquard I, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol. 2005;23:5795–804.PubMedCrossRefGoogle Scholar
  36. 36.
    Gold JS, Dematteo RP. Neoadjuvant therapy for gastrointestinal stromal tumor (GIST): racing against resistance. Ann Surg Oncol. 2007;14:1247–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Bilimoria KY, Bentrem DJ, Feinglass JM, Stewart AK, Winchester DP, Talamonti MS, et al. Directing surgical quality improvement initiatives: comparison of perioperative mortality and long-term survival for cancer surgery. J Clin Oncol. 2008;26:4626–33.PubMedCrossRefGoogle Scholar
  38. 38.
    Birkmeyer JD, Sun Y, Wong SL, Stukel TA. Hospital volume and late survival after cancer surgery. Ann Surg. 2007;245:777–83.PubMedCrossRefGoogle Scholar
  39. 39.
    Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS. National failure to operate on early stage pancreatic cancer. Ann Surg. 2007;246:173–80.PubMedCrossRefGoogle Scholar
  40. 40.
    Bilimoria KY, Balch CM, Bentrem DJ, Talamonti MS, Ko CY, Lange JR, et al. Complete lymph node dissection for sentinel node-positive melanoma: assessment of practice patterns in the United States. Ann Surg Oncol. 2008;15:1566–76.PubMedCrossRefGoogle Scholar
  41. 41.
    Bilimoria KY, Bentrem DJ, Ko CY, Tomlinson JS, Stewart AK, Winchester DP, et al. Multimodality therapy for pancreatic cancer in the U.S.: utilization, outcomes, and the effect of hospital volume. Cancer. 2007;110:1227–34.PubMedCrossRefGoogle Scholar
  42. 42.
    Bilimoria KY, Balch CM, Wayne JD, Chang DC, Palis BE, Dy SM, et al. Health care system and socioeconomic factors associated with variance in use of sentinel lymph node biopsy for melanoma in the United States. J Clin Oncol. 2009;27:1857–63.PubMedCrossRefGoogle Scholar
  43. 43.
    Andtbacka RH, Ng CS, Scaife CL, Cormier JN, Hunt KK, Pisters PW, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol. 2007;14:14–24.PubMedCrossRefGoogle Scholar
  44. 44.
    Ayanian JZ, Zaslavsky AM, Fuchs CS, Guadagnoli E, Creech CM, Cress RD, et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol. 2003;21:1293–300.PubMedCrossRefGoogle Scholar
  45. 45.
    Cress RD, Zaslavsky AM, West DW, Wolf RE, Felter MC, Ayanian JZ. Completeness of information on adjuvant therapies for colorectal cancer in population-based cancer registries. Med Care. 2003;41:1006–12.PubMedCrossRefGoogle Scholar
  46. 46.
    Du XL, Key CR, Dickie L, Darling R, Delclos GL, Waller K, et al. Information on chemotherapy and hormone therapy from tumor registry had moderate agreement with chart reviews. J Clin Epidemiol. 2006;59:53–60.PubMedCrossRefGoogle Scholar
  47. 47.
    Rubin JL, Taylor DC, Sanon M, Coombs JH, Bollu VK. Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors. J Manag Care Pharm. 2010;16:482–91.PubMedGoogle Scholar
  48. 48.
    Schuster MA, McGlynn EA, Brook RH. How good is the quality of health care in the United States? Milbank Q. 2005;83:843–95.PubMedCrossRefGoogle Scholar
  49. 49.
    Brook RH. Assessing the appropriateness of care—its time has come. JAMA. 2009;302:997–8.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2011

Authors and Affiliations

  • Karl Y. Bilimoria
    • 1
    • 2
  • Jeffrey D. Wayne
    • 2
  • Ryan P. Merkow
    • 2
  • Daniel E. Abbott
    • 1
  • Janice N. Cormier
    • 1
  • Barry W. Feig
    • 1
  • Kelly K. Hunt
    • 1
  • Peter W. T. Pisters
    • 1
  • Raphael Pollock
    • 1
  • David J. Bentrem
    • 2
    • 3
  1. 1.Department of Surgical OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Department of Surgery, Feinberg School of MedicineNorthwestern UniversityChicagoUSA
  3. 3.Department of SurgeryJesse Brown VA Medical CenterChicagoUSA

Personalised recommendations